Harnessing GSK-3β inhibition for lung cancer therapy: emerging opportunities and challenges
Emad H M Hassanein1, Hanan S Althagafy2, Hanan H Abd- ElHafeez3
1Department of Pharmacology and Toxicology, Faculty of Pharmacy, Al-Azhar University, Assiut Branch, Assiut, 71524, Egypt. emadhassanien@azhar.edu.eg.
Abstract:
Lung cancer (LC) primarily affects men and is the third most common cause of cancer-related death worldwide. Treatment for LC involves many phases, each with specific challenges arising from the characteristics of malignancy and the limitations of chemotherapy. GSK-3β, a serine/threonine kinase factor, is essential for several signals that control important cellular functions and a variety of diseases, including cancer. GSK-3β regulates transcription factors through phosphorylation, which in turn activates signaling pathways such as PI3K/AKT/mTOR, Wnt/β-catenin, and NF-κB. These signaling pathways might affect LC. Additionally, targeting GSK-3β offers a promising approach to overcoming drug resistance in cancer therapy. Inhibiting GSK-3β has been demonstrated to boost chemotherapy sensitivity, making cancer cells more responsive to treatment, while also suppressing their growth and survival. We provide an in-depth analysis of scientific literature that investigates the manner in which inhibiting GSK-3β with various compounds might be used to treat, impede, and improve the therapeutic response in LC cells. Next, we suggested that GSK-3β inhibition might be a therapeutic option to increase patient survival in patients with LC. For this reason, further studies on this subject will be required in the coming years.
Insights
Inhibiting GSK-3β (glycogen synthase kinase 3 beta) may improve lung cancer treatment. This approach can enhance chemotherapy sensitivity and suppress cancer cell growth, potentially increasing patient survival.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Lung cancer (LC) is a leading cause of cancer death, with treatment challenges including chemotherapy limitations.
- Glycogen synthase kinase 3 beta (GSK-3β) is a kinase crucial for cellular functions and implicated in various diseases, including cancer.
- GSK-3β influences key signaling pathways like PI3K/AKT/mTOR, Wnt/β-catenin, and NF-κB, which may play a role in LC development and progression.
Purpose of the Study:
- To analyze scientific literature on the potential of inhibiting GSK-3β for lung cancer treatment.
- To investigate how targeting GSK-3β can overcome drug resistance and improve therapeutic responses in LC cells.
- To evaluate GSK-3β inhibition as a strategy to enhance chemotherapy sensitivity and patient survival in lung cancer.
Main Methods:
- Literature review and analysis of scientific studies.
- Investigation of GSK-3β's role in cell signaling pathways relevant to lung cancer.
- Assessment of the impact of GSK-3β inhibition on cancer cell growth, survival, and chemotherapy sensitivity.
Main Results:
- GSK-3β inhibition shows promise in overcoming drug resistance in cancer therapy.
- Inhibiting GSK-3β can enhance sensitivity to chemotherapy, leading to improved cancer cell response.
- Targeting GSK-3β may suppress lung cancer cell growth and survival.
Conclusions:
- GSK-3β inhibition represents a potential therapeutic strategy for lung cancer.
- Further research is warranted to explore GSK-3β inhibitors for improving lung cancer patient outcomes and survival.
- Targeting GSK-3β could be a valuable approach to enhance current lung cancer treatment regimens.
More Related Videos
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
06:03Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression
Published on: January 19, 2019
